IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11674967 B1

PDFFull Text
Date of Patent:
Jun. 13, 2023

Filed:

Sep. 04, 2020

Method of identifying potential inhibitors of apo tnfα trimers

Applicant:

Ucb Biopharma Srl, Brussels, BE;

Inventors:

James Philip O'Connell, Slough, GB;

John Robert Porter, Slough, GB;

Alastair Lawson, Slough, GB;

Boris Kroeplien, Slough, GB;

Stephen Edward Rapecki, Slough, GB;

Timothy John Norman, Slough, GB;

Graham John Warrellow, Slough, GB;

Tracy Lynn Arakaki, Slough, GB;

Alex Buntin Burgin, Slough, GB;

William Ross Pitt, Slough, GB;

Mark Daniel Calmiano, Slough, GB;

David Andreas Schubert, Slough, GB;

Daniel John Lightwood, Slough, GB;

Rebecca Jayne Munro, Slough, GB;

Assignee:

UCB BIOPHARMA SRL, Brussels, BE;

Attorney:

Medler Ferro Woodhouse & Mills

Primary Examiner:

Elly-Gerald Stoica

Int. Cl.
CPC ...
G01N 33/68 (2006.01); C07D 401/14 (2006.01); C07K 14/525 (2006.01); C07D 471/00 (2006.01); C07K 14/705 (2006.01); C07K 16/24 (2006.01); C07D 213/72 (2006.01); C07D 235/04 (2006.01); C07D 239/26 (2006.01); C07D 471/04 (2006.01); A61K 47/64 (2017.01); A61P 37/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6845 (2013.01); A61K 47/6425 (2017.08); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07D 213/72 (2013.01); C07D 235/04 (2013.01); C07D 239/26 (2013.01); C07D 401/14 (2013.01); C07D 471/00 (2013.01); C07D 471/04 (2013.01); C07K 14/525 (2013.01); C07K 14/70575 (2013.01); C07K 16/241 (2013.01); G01N 33/6854 (2013.01); G01N 33/6863 (2013.01); C07K 2317/55 (2013.01); C07K 2317/92 (2013.01); G01N 2333/525 (2013.01); G01N 2500/02 (2013.01);
Abstract

A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

Find Patent Forward Citations

Loading…